More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.25B
EPS
-0.13
P/E ratio
--
Price to sales
2.69
Dividend yield
--
Beta
1.092601
Previous close
$3.76
Today's open
$3.92
Day's range
$3.80 - $4.09
52 week range
$2.23 - $6.51
show more
CEO
Michael E. Castagna
Employees
592
Headquarters
Danbury, CT
Exchange
NASDAQ Global Market
Shares outstanding
321640118
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
MannKind Q3 Earnings Call Highlights
MannKind NASDAQ: MNKD expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza launches gain traction.
MarketBeat • Nov 6, 2026

MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates
MannKind (MNKD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.03 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 6, 2026

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday, November 5, 2026.
GlobeNewsWire • Oct 29, 2026

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
MannKind NASDAQ: MNKD Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF, following early safety and tolerability results that did not show the gastrointestinal issues often associated with oral nintedanib.
MarketBeat • Oct 20, 2026

This MannKind Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Benzinga • Oct 19, 2026

MannKind to Participate in the Chardan Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on innovation across chronic respiratory diseases at the Chardan Healthcare Conference. Management will also participate in one-on-one meetings with investors during the conference.
GlobeNewsWire • Oct 14, 2026

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase 1b data for MNKD-201 in idiopathic pulmonary fibrosis, or IPF.
MarketBeat • Sep 17, 2026

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule
MannKind Corporation (NASDAQ:MNKD) shares are trading lower on Wednesday as traders react to the company's entry into a licensing and collaboration deal tied to an inhaled, rapid-acting GLP-1 program.
Benzinga • Sep 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell MannKind Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.